Loading
Loading…
Loading…
| # | Schedule | Awarded To | Bids | Value |
|---|---|---|---|---|
| 1 | Schedule 1 | Abishek medical devicesLikely | 1 | ₹63,279 |
| 2 | Schedule 2 | I C DISPOSABLE AND SURGICALLikely | 1 | ₹1,260 |
| 3 | Schedule 3 | SUNIL PHARMACYLikely | 1 | ₹3,840 |
| 4 | Schedule 4 | SUNIL PHARMACYLikely | 1 | ₹1,188 |
| 5 | Schedule 5 | SUNIL PHARMACYLikely | 1 | ₹11,640 |
Tender Value
Refer Docs
EMD Value
Exempted
Closing Date
8 Jul 2026, 11:00 amClosed
Inj Serplulimab 300mg
Inj Paclitaxel 100 mg
Inj Carboplatin 150 mg
Inj Filgrastim 300 mcg
Inj Leuprolide 22 point 5mg
9529634
GEM/2026/B/7719120
Two Packet Bid
Inj Serplulimab 300mg,Inj Paclitaxel 100 mg,Inj Carboplatin 150 mg,Inj Filgrastim 300 mcg,Inj Leupr
Hyderabad, Telangana
Item wise evaluation
BOQ
5 documents required · 5 mandatory
2 yrs
20%
Exempted
Yes
8 Jul 2026
28 Jun 2026
8 Jul 2026
| Item No | Item Title | Description | Qty | Unit | Consignee | Delivery (days) |
|---|---|---|---|---|---|---|
| 1 | Inj Serplulimab 300mg | inj | 3 | No | HYDERABAD | 21 |
| 2 | Inj Paclitaxel 100 mg | inj | 3 | No | HYDERABAD | 21 |
| 3 | Inj Carboplatin 150 mg | inj | 3 | No | HYDERABAD | 21 |
| 4 | Inj Filgrastim 300 mcg | inj | 6 | No | HYDERABAD | 21 |
| 5 | Inj Leuprolide 22 point 5mg | inj | 3 | No | HYDERABAD | 21 |
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
bid_9529634.pdf
GEM_BID • 0.11 MB
undertaking-21_echs_2026-06-28-10-12-03_76b985bb73bc8cc4f48074659e94b34e.pdf
BOQ • 0.78 MB
boq_item_sample_file_2026-06-28-10-12-03_20ab1eb6b10e223e40721ad1b61690fb.csv
BOQ • 0.00 MB
gtc.pdf
GEM_OTHER • 0.71 MB
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .